FIG 1.

Expression of antiviral factors according to HIV-1 infection status and compartment. (A to C) Expression of the IFN-I-responsive gene (MxA) (A), TRIM5α (B), and TRIM22 (C) in PBMCs from HIV-1-uninfected versus -infected subjects. (D to F) Expression of MxA (D), TRIM5α (E), and TRIM22 (F) in PBMCs versus CSF-derived cells from chronically infected patients. The samples from participants with primary infection were all collected within 12 months of infection. One time point, closest to 12 months postinfection, was used per participant (n = 28). For HIV-1-negative participants, only those who remained HIV-1 negative during the entire follow-up period (2 years) were included in this analysis (n = 19). The chronically infected group consisted of participants presenting with chronic meningitis (n = 26). Matched CSF samples and PBMCs from the same patients were analyzed (n = 26). Data are depicted as normalized ratios of MxA, TRIM5α, or TRIM22 to GAPDH. Median expression levels between HIV-negative and HIV-positive samples were compared. (G to I) Correlations (Pearson) between MxA and TRIM5α (G), TRIM22 and MxA (H), and TRIM22 and TRIM5α (I) in both CSF samples and PBMCs from patients with chronic HIV-1 infection.